Tag Archives: risk management
December 2018 Br J Cardiol 2018;25:127–9 doi:10.5837/bjc.2018.030
Prescribing for patients with type 2 diabetes and CV disease: should we be following the Scottish example?
Sean L Zheng
Dr Sean L Zheng CVOTs The key studies evaluated sodium-glucose co-transporter 2 (SGLT2) inhibitors – empagliflozin (EMPA-REG OUTCOME)4 and canagliflozin (CANVAS)5 – and glucagon-like peptide 1 (GLP-1) receptor agonists – liraglutide (LEADER)6 and semaglutide (SUSTAIN-6)7 – in patients with type 2 diabetes and cardiovascular disease or elevated cardiovascular risk (table 1). In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose) study, the use of empagliflozin resulted in 38% and 35% reductions in cardiovascular death and heart failure hospitalisation, r
January 2003 Br J Cardiol 2003;10:70-2
Amiodarone monitoring: involving patients in risk management
Jill Murie
No content available
For healthcare professionals only
